Trevogrumab is an investigational antibody targeting myostatin. The COURAGE program has examined it alongside semaglutide, asking whether it can reduce the loss of lean tissue during weight loss.[1]
- Class
- Anti-myostatin antibody
- Program
- COURAGE
- Source type
- Sponsor report · Oct 2026
What is the research question?
The question is not simply whether body weight falls. It is whether a combination changes the composition of that weight loss. Regeneron reported new 52-week COURAGE results on October 1, 2026.[1]
That makes the population, background medicine, follow-up period, and measurement method central to the answer. A result observed during semaglutide treatment should not be described as a stand-alone result in healthy athletes.
What does “muscle preservation” mean here?
The sponsor report includes whole-body lean-mass measurements using DXA and thigh-muscle measurements in an MRI subgroup. Those are different measures. A headline percentage from one cannot substitute for the other.[1]
To interpret any preservation claim, ask what loss occurred in the comparison group, what loss remained in the treatment group, and whether the figure is an absolute change or a relative difference. Less loss is also different from a gain above baseline.
What is the evidence status?
The October release is a sponsor announcement of trial findings. It described conference presentation and a paper in press. Readers should look for the complete publication and any later updates before treating the announcement as a final account.[1]
A press release can identify an important result, but its purpose and level of detail differ from a full methods section, analysis plan, and adverse-event table. This is an evidence-format distinction, not a conclusion that the result is either true or false.
What should a useful summary include?
A clear summary names the treatment combination, labels the sponsor source, separates MRI from DXA, and explains the comparator. It also avoids claiming a functional benefit unless a functional measure supports one.
The COURAGE evidence note explains the reported results. For the broader differences between mechanisms, use the compound comparison.
Questions, answered.
Is trevogrumab a short peptide?
It is an antibody. The generic search phrase “myostatin peptide” does not identify its molecular class.
Does preservation mean that muscle increased?
Not necessarily. A group can lose less tissue than a comparison group while still ending below its own baseline.
Sources & further reading
Primary research and official records used for this page. Study results apply to the populations and interventions described.
- Phase 2 COURAGE Trial: 52-week trevogrumab findingsRegeneron · October 1, 2026 · Sponsor-reported results; distinct from a full paper